|
1.
|
|
10 p, 1.6 MB |
Assessment of the level III of Inoue by preoperative endoscopic ultrasound and elastography : a novel approach to predict a periarterial divestment technique in borderline resectable (BR) or locally advanced (LA) pancreatic adenocarcinoma-How I do it
/
Alberti Delgado, Piero (Universitat Autònoma de Barcelona. Departament de Cirurgia) ;
Pando, Elizabeth (Universitat Autònoma de Barcelona. Departament de Cirurgia) ;
Abu-Suboh Abadia, Monder (Hospital Universitari Vall d'Hebron) ;
Masachs, Miquel (Hospital Universitari Vall d'Hebron) ;
Merino, Xavier (Hospital Universitari Vall d'Hebron) ;
Salcedo, Maite (Hospital Universitari Vall d'Hebron) ;
Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ;
Balsells, Joaquim (Hospital Universitari Vall d'Hebron) ;
Charco, Ramon (Hospital Universitari Vall d'Hebron)
Background: Periarterial divestment is a surgical technique to approach borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) with arterial involvement. There are no reports in the literature regarding the role of endoscopic ultrasound and elastography (EUS-EG) in exploring the integrity of Inoue's level III and its correlation with the periarterial divestment technique feasibility. [...]
2023 -  10.1007/s00423-023-03105-x
Langenbeck's archives of surgery, Vol. 408 (2023) , art. 367
|
|
|
2.
|
|
11 p, 1.9 MB |
Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice
/
Laquente, B. (Hospital Duran i Reynals (Hospitalet del Llobregat)) ;
Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ;
Bugés, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martín, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
García, C. (Complejo Hospitalario de Burgos) ;
Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Merino, S. (Hospital Sant Joan de Reus) ;
Visa, Laura (Hospital del Mar (Barcelona, Catalunya)) ;
Martín, T. (Hospital Universitario de Salamanca) ;
Pedraza, M. (Complejo Asistencial Universitario de León) ;
Carnero, B. (Hospital El Bierzo) ;
Guardeño, R. (Institut Català d'Oncologia) ;
Verdaguer, Helena (Vall d'Hebron Institut d'Oncologia) ;
Mut, A. (Celgene S.L.U) ;
Vilanova, D. (Celgene S.L.U) ;
García, A. (Institut Català d'Oncologia) ;
Universitat Autònoma de Barcelona
Despite advances in surgery, radiotherapy, and chemotherapy, pancreatic adenocarcinoma often progresses rapidly and causes death. The physical decline of these patients is expected to impact their quality of life (QoL). [...]
2020 - 10.1186/s12904-020-00610-4
BMC Palliative Care, Vol. 19 Núm. 1 (october 2020) , p. 610
|
|
|
3.
|
|
10 p, 3.2 MB |
Liquid biopsy after resection of pancreatic adenocarcinoma and its relation to oncological outcomes. Systematic review and meta-analysis
/
Vidal, Laura (Hospital Universitari Vall d'Hebron) ;
Pando, Elizabeth (Hospital Universitari Vall d'Hebron) ;
Blanco Cuso, Laia (Hospital Universitari Vall d'Hebron) ;
Fabregat-Franco, Carles (Hospital Universitari Vall d'Hebron) ;
Sierra, Alexandre (Hospital Universitari Vall d'Hebron) ;
Macarulla Mercadé, Teresa (Hospital Universitari Vall d'Hebron) ;
Balsells, Joaquim (Hospital Universitari Vall d'Hebron) ;
Charco, Ramon (Hospital Universitari Vall d'Hebron) ;
Vivancos, Ana (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
It has been hypothesised that manipulation during surgery releases tumoral components into circulation. We investigate the effect of surgery on plasma-borne DNA biomarkers and the oncological outcomes in resectable pancreatic ductal adenocarcinoma (PDAC). [...]
2023 - 10.1016/j.ctrv.2023.102604
Cancer Treatment Reviews, Vol. 120 (2023) , p. 102604
|
|
|
4.
|
|
7 p, 1.3 MB |
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
/
Melisi, Davide (University of Verona, Piazzale Ludovico Antonio Scuro) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ;
Pezet, Denis (Centre Hospitalier Universitaire) ;
Deplanque, Gael (Hôpital Riviera-Chablais) ;
Fuchs, Martin (Klinikum Bogenhausen, Städtisches Klinikum München GmbH, Englschalkinger Road 77, 81925 Munich, Germany) ;
Trojan, Jorg (Goethe University Medical Center) ;
Oettle, Helmut (Onkologische und Hämatologische Schwerpunktpraxis, Friedrichshafen, Germany) ;
Kozloff, Mark (Ingalls Memorial Hospital) ;
Cleverly, Ann (Eli Lilly and Company, Erl Wood Manor, Windlesham) ;
Smith, Claire (formerly of Eli Lilly and Company) ;
Estrem, Shawn T. (Eli Lilly and Company, Lilly Corporate Center) ;
Gueorguieva, Ivelina (Eli Lilly and Company, Erl Wood Manor, Windlesham) ;
Lahn, Michael M. F. (Wisconsin Ave., #8008, Bethesda, MD 20815 USA) ;
Blunt, Al (Advaxis, Inc) ;
Benhadji, Karim A. (Eli Lilly and Company) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Universitat Autònoma de Barcelona
Galunisertib is the first-in-class, first-in-human, oral small-molecule type I transforming growth factor-beta receptor (ALK5) serine/threonine kinase inhibitor to enter clinical development. The effect of galunisertib vs. [...]
2018 - 10.1038/s41416-018-0246-z
British Journal of Cancer, Vol. 119 (october 2018) , p. 1208-1214
|
|
|
5.
|
|
9 p, 351.5 KB |
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS -mutant metastatic colorectal cancer
/
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Chianese, Chiara (Vall d'Hebron Institut d'Oncologia) ;
Sanz-García, Enrique (Vall d'Hebron Institut d'Oncologia) ;
Martinelli, Erica (Università della Campania 'L. Vanvitelli') ;
Noguerido, Alba (Vall d'Hebron Institut d'Oncologia) ;
Mancuso, Francesco M. (Vall d'Hebron Institut d'Oncologia) ;
Caratù, Ginevra (Vall d'Hebron Institut d'Oncologia) ;
Matito, Judit (Vall d'Hebron Institut d'Oncologia) ;
Grasselli, Julieta (Vall d'Hebron Institut d'Oncologia) ;
Cardone, Claudia (Università della Campania 'L. Vanvitelli') ;
Esposito Abate, Riziero (Istituto Nazionale Tumori 'Fondazione Giovanni Pascale' IRCCS) ;
Martini, Giulia ;
Santos Vivas, Cristina (Universitat de Barcelona) ;
Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ;
Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ;
Garcia, Ariadna (Vall d'Hebron Institut d'Oncologia) ;
Mulet, Nuria (Universitat de Barcelona) ;
Maiello, Evaristo (IRCCS Casa Sollievo della Sofferenza) ;
Normanno, Nicola (Istituto Nazionale Tumori 'Fondazione Giovanni Pascale' IRCCS) ;
Jones, Frederick (Sysmex Inostics) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Ciardello, Fortunato (Università della Campania 'L. Vanvitelli') ;
Salazar, Ramon (Universitat de Barcelona) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Despite major advances in the treatment of metastatic colorectal cancer (mCRC), the survival rate remains very poor. This study aims at exploring the prognostic value of RAS -mutant allele fraction (MAF) in plasma in mCRC. [...]
2019 - 10.1002/1878-0261.12547
Molecular Oncology, Vol. 13 (july 2019) , p. 1827-1835
|
|
|
6.
|
|
8 p, 357.7 KB |
Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
/
Grasselli, Julieta (Institut Català d'Oncologia) ;
Elez, Elena (Universitat Autònoma de Barcelona) ;
Caratù, Ginevra (Vall d'Hebron Institut d'Oncologia) ;
Matito, Judit (Vall d'Hebron Institut d'Oncologia) ;
Santos Vivas, Cristina (Institut Català d'Oncologia) ;
Macarulla Mercadé, Teresa (Hospital Universitari Vall d'Hebron) ;
Vidal, J. (Hospital del Mar (Barcelona, Catalunya)) ;
Garcia, M.. (Institut Català d'Oncologia) ;
Viéitez, J. M. (Hospital Universitario Central de Asturias) ;
Páez, David (Institut d'Investigació Biomèdica Sant Pau) ;
Falcó, E. (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Lopez Lopez, C. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Aranda Aguilar, Enrique (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Jones, F. (Sysmex Inostics, Mundelein, USA) ;
Sikri, V (Sysmex Inostics, Mundelein, USA) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Fasani, R. (Vall d'Hebron Institut d'Oncologia) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Montagut, Clara (Hospital del Mar (Barcelona, Catalunya)) ;
Azuara, D. (Institut Català d'Oncologia) ;
Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ;
Salazar, R. (Institut Català d'Oncologia) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Circulating tumor DNA (ctDNA) is a potential source for tumor genome analysis. We explored the concordance between the mutational status of RAS in tumor tissue and ctDNA in metastatic colorectal cancer (mCRC) patients to establish eligibility for anti-epidermal growth factor receptor (EGFR) therapy. [...]
2017 - 10.1093/annonc/mdx112
Annals of oncology, Vol. 28 (march 2017) , p. 1294-1301
|
|
|
7.
|
|
39 p, 4.7 MB |
mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer
/
Zabala-Letona, Amaia (Centro de Investigación Biomédica en Red de Cáncer) ;
Arruabarrena-Aristorena, Amaia (CIC bioGUNE) ;
Martín Martín, Natalia (Centro de Investigación Biomédica en Red de Cáncer) ;
Fernández Ruiz, Sonia (Centro de Investigación Biomédica en Red de Cáncer) ;
Sutherland, James D. (CIC bioGUNE) ;
Clasquin, Michelle (AGIOS Pharmaceuticals) ;
Tomás Cortázar, Julen (CIC bioGUNE) ;
Jiménez, José (Hospital Universitari Vall d'Hebron) ;
Torres Ramírez, Inés Ma. de (Hospital Universitari Vall d'Hebron) ;
Quang, Phong (AGIOS Pharmaceuticals) ;
Ximénez-Embún, Pilar (Centro Nacional de Investigaciones Oncológicas) ;
Bago, Ruzica (MRC Protein Phosphorylation and Ubiquitylation Unit) ;
Ugalde Olano, Aitziber (Hospital de Basurto (Bilbao, Biscaia)) ;
Loizaga Iriarte, Ana (Hospital de Basurto (Bilbao, Biscaia)) ;
Lacasa Viscasillas, Isabel (Hospital de Basurto (Bilbao, Biscaia)) ;
Unda, Miguel (Hospital de Basurto (Bilbao, Biscaia)) ;
Torrano, Verónica (Centro de Investigación Biomédica en Red de Cáncer) ;
Cabrera, Diana (CIC bioGUNE) ;
van Liempd, Sebastiaan M. (CIC bioGUNE) ;
Cendon, Ylenia (Universidad Autónoma de Madrid) ;
Castro, Elena (Centro Nacional de Investigaciones Oncológicas) ;
Murray, Stuart (AGIOS Pharmaceuticals) ;
Revandkar, Ajinkya (University of Lausanne) ;
Alimonti, Andrea (University of Lausanne) ;
Zhang, Yinan (Harvard School of Public Health) ;
Barnett, Amelia (AGIOS Pharmaceuticals) ;
Lein, Gina (AGIOS Pharmaceuticals) ;
Pirman, David (AGIOS Pharmaceuticals) ;
Cortazar, Ana Rosa (CIC bioGUNE) ;
Arreal, Leire (CIC bioGUNE) ;
Prudkin, Ludmila (Hospital Universitari Vall d'Hebron) ;
Astobiza, Ianire (CIC bioGUNE) ;
Valcárcel Jiménez, Lorea (CIC bioGUNE) ;
Zúñiga-García, Patricia (CIC bioGUNE) ;
Fernández Domínguez, Itziar (CIC bioGUNE) ;
Piva, Marco (CIC bioGUNE) ;
Caro-Maldonado, Alfredo (CIC bioGUNE) ;
Sánchez Mosquera, Pilar (CIC bioGUNE) ;
Castillo Martín, Mireia (Fundação Champalimaud) ;
Serra, Violeta (Hospital Universitari Vall d'Hebron) ;
Beraza, Naiara (CIC bioGUNE) ;
Gentilella, Antonio (Institut Català d'Oncologia) ;
Thomas, George (Institut Català d'Oncologia) ;
Azkargorta, Mikel (Carlos III Networked Proteomics Platform) ;
Elortza, Felix (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Farràs, Rosa (Centro de Investigación Príncipe Felipe (València)) ;
Olmos, David (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Efeyan, Alejo (Centro Nacional de Investigaciones Oncológicas) ;
Anguita, Juan (Ikerbasque) ;
Muñoz, Javier (Carlos III Networked Proteomics Platform) ;
Falcón Pérez, Juan M. (Ikerbasque) ;
Barrio, Rosa (CIC bioGUNE) ;
Macarulla Mercadé, Teresa (Hospital Universitari Vall d'Hebron) ;
Mato, José M. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Martínez Chantar, Maria L. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Cordon Cardo, Carlos (Icahn School of Medicine at Mount Sinai) ;
Aransay, Ana M. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Marks, Kevin (AGIOS Pharmaceuticals) ;
Baselga Torres, Josep, 1959-2021, (Memorial Sloan Kettering Cancer Center) ;
Tabernero, Josep (Hospital Universitari Vall d'Hebron) ;
Nuciforo, Paolo (Hospital Universitari Vall d'Hebron) ;
Manning, Brendan D. (Harvard School of Public Health) ;
Marjon, Katya (AGIOS Pharmaceuticals) ;
Carracedo, Arkaitz (University of the Basque Country) ;
Universitat Autònoma de Barcelona
Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation,. Here we show that mTORC1 regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. [...]
2017 - 10.1038/nature22964
Nature, Vol. 547 (July 2017) , p. 109-113
|
|
|
8.
|
|
10 p, 506.2 KB |
Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights
/
Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ;
Elez, Elena (Hospital Universitari Vall d'Hebron) ;
Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ;
Matos, Ignacio (Vall d'Hebron Institut d'Oncologia) ;
Sanz García, Enrique (Vall d'Hebron Institut d'Oncologia) ;
Ortiz, Carolina (Vall d'Hebron Institut d'Oncologia) ;
Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ;
Saurí Nadal, Tamara (Vall d'Hebron Institut d'Oncologia) ;
Verdaguer, Helena (Vall d'Hebron Institut d'Oncologia) ;
Vilaró, Marta (Vall d'Hebron Institut d'Oncologia) ;
Ruiz-Pace, Fiorella (Vall d'Hebron Institut d'Oncologia) ;
Viaplana, Cristina (Vall d'Hebron Institut d'Oncologia) ;
García Rodríguez, Ariadna (Vall d'Hebron Institut d'Oncologia) ;
Landolfi, Stefania (Universitat Autònoma de Barcelona) ;
Palmer, Héctor G (Vall d'Hebron Institut d'Oncologia) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia)
Sequencing of tumors is now routine and guides personalized cancer therapy. Mutant allele fractions (s, or the 'mutation dose') of a driver gene may reveal the genomic structure of tumors and influence response to targeted therapies. [...]
2017 - 10.1002/1878-0261.12099
Molecular Oncology, Vol. 11, Issue 9 (September 2017) , p. 1263-1272
|
|
|
9.
|
|
8 p, 207.5 KB |
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS -mutated metastatic colorectal cancer
/
Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ;
Cervantes, Andrés (Universitat de València. Biomedical Research Institute) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Roselló, Susana (Universitat de València. Biomedical Research Institute) ;
Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Tejpar, Sabine (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Prenen, H. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Martinelli, E. (Second University of Naples. Department of Experimental and Clinical Medicine) ;
Troiani, T. (Second University of Naples. Department of Experimental and Clinical Medicine) ;
Laffranchi, B. (Merck Serono SA) ;
Jego, V (Merck Serono SA) ;
von Richter, O. (Merck KGaA) ;
Ciardiello, Fortunato (Second University of Naples. Department of Experimental and Clinical Medicine) ;
Universitat Autònoma de Barcelona
The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib. [...]
2015 - 10.1038/bjc.2015.144
British Journal of Cancer, Vol. 112 (June 2015) , p. 1874-1881
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
